Alprazolam-ritonavir interaction: implications for product labeling

Area of Science:

• Pharmacology
• Drug Metabolism
• Clinical Pharmacy

Background:

• Pharmacokinetic interactions of antiretroviral therapies can impact drug efficacy and toxicity.
• Ritonavir, a protease inhibitor, is notable for its dual role in inhibiting and inducing cytochrome P450 3A (CYP3A) activity.
• Understanding these interactions is crucial for managing co-administered medications.

Purpose of the Study:

• To investigate the in vitro and in vivo inhibitory effect of ritonavir on alprazolam metabolism.
• To assess the clinical implications of co-administering low-dose ritonavir with alprazolam.

Main Methods:

• In vitro studies using human liver microsomes to determine ritonavir's inhibition of alprazolam hydroxylation.
• A double-blind clinical study where subjects received alprazolam with either low-dose ritonavir or placebo.

Main Results:

• Ritonavir demonstrated potent in vitro inhibition of alprazolam metabolism, with an IC50 below therapeutic concentrations.
• In clinical trials, ritonavir significantly reduced alprazolam clearance and prolonged its elimination half-life.
• Co-administration led to amplified clinical effects of alprazolam, including sedation and cognitive impairment.

Conclusions:

• Short-term, low-dose ritonavir administration markedly impairs alprazolam clearance and intensifies clinical effects.
• Previous conclusions regarding ritonavir and alprazolam co-administration, based on extended exposure studies, may not apply to short-term use.
• Drug labeling should accurately reflect the complex and time-dependent nature of pharmacokinetic interactions involving antiretroviral therapies.